-
Next-Generation Actives: How Peptides Are Redefining Cosmeceutical Efficacy
Mar , 11 2026
Coined in 1984 by dermatologist Albert Kligman, the term “cosmeceuticals” describes products that bridge cosmetics and pharmaceuticals, offering both aesthetic and therapeutic benefits. Among active i...
read more
-
A Milestone Breakthrough: NMN Officially Approved as a New Cosmetic Ingredient by NMPA
Apr , 14 2026
On January 27, 2026, China’s National Medical Products Administration (NMPA) officially completed the filing and approval of Nicotinamide Mononucleotide (NMN) as a new cosmetic ingredient. This histor...
read more
-
Market Insight: ECO 2026 Highlights Orforglipron's Potential to Reshape the $100B Oral GLP-1 Market
May , 19 2026
The European Congress on Obesity (ECO 2026) has concluded, but the excitement surrounding Orforglipron (LY3502970) continues to reverberate throughout the global pharmaceutical industry. For millions ...
read more
-
Orforglipron vs. Semaglutide vs. Tirzepatide: The Ultimate 2026 Weight Loss Drug Comparison
May , 21 2026
1. Introduction: The GLP-1 Evolution The weight loss pharmaceutical market has dramatically shifted with the 2026 FDA approval of Orforglipron (Foundayo). This new oral, non-peptide agonist challenges...
read more
IPv6 network supported
English
中文
français
Deutsch
русский
español
português
العربية
日本語
한국의
Türkçe
